Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma

In the Checkmate-025 trial, nivolumab treatment prolonged overall survival among patients with previously treated advanced renal cell carcinoma (RCC) compared with treatment with everolimus. Although effective, nivolumab is associated with immune-related adverse events (irAEs). However, the occurren...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Shinro, Abe, Satoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256289/
https://www.ncbi.nlm.nih.gov/pubmed/32489885
http://dx.doi.org/10.1016/j.eucr.2020.101128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256289/
https://www.ncbi.nlm.nih.gov/pubmed/32489885
http://dx.doi.org/10.1016/j.eucr.2020.101128

Ejemplares similares